CDE Granted LM-108 Breakthrough Therapy Designation for MSI-H/dMMR Solid Tumors

2025-02-08
Share:

SHANGHAI, February 8^th, 2025 – LaNova Medicines Ltd. announced CDE has granted LM-108 (anti-CCR8 mAb) Breakthrough Therapy Designation. This designation is for the treatment of patients with advanced solid tumors who have disease progression following immune checkpoint inhibitor treatment and are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Previous

LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-302 in Combination with Anti-PD-1 Antibody
Next

LaNova Medicines Announces IND Approval of LM-168 by US FDA